Skip to main content

Table 4 Characteristics of included observational studies

From: Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

Study

Study design

Data source

Countries involved

Funding

Total number of patients

Follow up (years)

Male (n, %)

Mean age (years)

Mean BMI (kg/m2)

Mean HbA1c (%)

Mean FPG (mmol/L)

Mean diabetes duration (years)

CVD at baseline

Studies reporting heart failure

 NCT01060059 2013 [66]

Prospective cohort study

Real world data

Italy

Private for-profit funding

882

1

493 (55.9)

62.5

NR

8.9

NR

NR

NR

 Kannan 2015 [17]a

Retrospective cohort study

Electronic health records

U.S.

No funding

13,185

4b

7827 (54.6)

60.6

32.6c

NR

NR

NR

Included patients had no history of CVD or congestive heart failure at baseline

 Paul 2015 [18]

Retrospective cohort study

Claims data

U.S.

NR

39,225

3.5b

18093 (46.1)

58.2

35.3

7.9

NR

1.3

Included patients had CVD or no CVD at baseline

Studies reporting hospitalization for heart failure

 Yu 2015 [19]a

Nested case–control study

Electronic medical records

UK

Public funding

57,737

NA

32795 (56.8)

61.6

NR

NR

NR

2.3

Included patients had CVD or no CVD at baseline

  1. aThese two studies accessed incretin agents (both glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) and the risk of heart failure, so the data above were the characteristics of total patients included
  2. BMI body mass index, FPG fasting plasma glucose, CVD cardiovascular disease, NR not reported, NA not applicable
  3. bmedian follow-up (years); cMedian BMI (kg/m2)